Exclusive: Oxfordshire-based Emergex gets go-ahead for trials in Switzerland for skin patch vaccine
An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.
Emergex was set up in Abingdon in 2016 to develop T-cell vaccines, the brainchild of Prof Thomas Rademacher, the firm’s chief executive and professor emeritus of molecular medicine at the University College London medical school.
Continue reading...source https://www.theguardian.com/society/2021/nov/15/uk-firm-to-trial-t-cell-covid-vaccine-that-could-give-longer-immunity
No comments:
Post a Comment